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Evidence from clinical patient populations indicates that affective dysregulation is strongly 
associated with reality distortion, suggesting that a process of misassignment of emotional 
salience may underlie this connection. To examine this in more detail without clinical 
confounds, affective regulation-reality distortion relationships, and their clinical relevance, 
were examined in a German prospective cohort community study. A cohort of 2524 
adolescents and young adults aged 14–24 years at baseline was examined by experienced 
psychologists. Presence of psychotic experiences and (hypo)manic and depressive symptoms 
was assessed at 2 time points (3.5 and up to 10 years after baseline) using the Munich-
Composite International Diagnostic Interview. Associations were tested between level of 
affective dysregulation on the one hand and incidence of psychotic experiences, persistence of 
these experiences, and psychotic Impairment on the other. Most psychotic experiences 
occurred in a context of affective dysregulation, and bidirectional dose-response was apparent 
with greater level of both affective dysregulation and psychotic experiences. Persistence of 
psychotic experiences was progressively more likely with greater level of (hypo)manic 
symptoms (odds ratio [OR] trend 5 1.51, P < .001) and depressive symptoms (OR trend 5 
1.15, P 5 .012). Similarly, psychotic experiences of clinical relevance were progressively 
more likely to occur with greater level of affective dysregulation (depressive symptoms: OR 
trend 5 1.28, P 5 .002; (hypo)manic symptoms: OR trend 5 1.37, P 5 .036). Correlated genetic 
liabilities underlying affective and nonaffective psychotic syndromes may be expressed as 
correlated dimensions in the general population. Also, affective dysregulation may contribute 
causally to the persistence and clinical relevance of reality distortion, possibly by facilitating a 
mechanism of aberrant salience attribution.  
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Introduction  
 
Evidence from multiple domains indicates that affective dysregulation is strongly associated 
with reality distortion.1,2 Genetic epidemiological studies have demonstrated that the liabilities 
for bipolar disorder and schizophrenia are correlated.3–5 Psychopathological studies have 
demonstrated that psychotic experiences are reported within the context of a range of affective 
clinical disorders,6,7 and conversely, high rates of affective symptoms have been demonstrated 
in patients diagnosed with Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV), nonaffective psychotic disorders,8,9 and schizotypy.10 Specific aspects of 
delusional content and severity of psychotic experiences are associated with dysfunctional 
emotional processes.11–13 Although most of the work in this area is cross-sectional and 
conducted in clinical samples, making it difficult to disentangle the direction of effects 
between affective and cognitive processes, and to distinguish between illness cause and illness 
consequence, the strong and consistent associations between affective states and reality 
distortion may imply causality.  
 
Experimental work by Holt and colleagues14 indicates that patients with a diagnosis of 
schizophrenia who had delusions were more likely to assign (negative) affective meanings to 
neutral stimuli compared with those without delusional ideation. The magnitude of this 
response bias correlated with the severity of delusions. The findings were interpreted as 
consistent with an inappropriate activation of a stimulus-independent internal „salience 
detector,“ leading to misassignment of emotional salience to neutral or abmiguous stimuli, 
and ultimately to the formation of delusions.14 Thus, affective dysregulation may result in 
maladaptive appraisal patterns of events, triggering a search for an explanation of their 
meaning that in turn increases the risk for positive psychotic experiences in vulnerable 
individuals.15 Dysregulation in dopamine transmission, facilitating stimulus-independent 
release of dopamine, causing aberrant assignment of salience and motivational significance to 
external objects (leading to delusions) and internal representations of percepts and memories 
(leading to hallucinations) may represent the underlying neurobiological vulnerability 
mediating the process of reality distortion.16  
 
Research on associations between variable clinical characteristics such as affective symptoms 
and psychotic experiences in clinical samples cannot examine to what degree such 
associations may arise as a result of the illness itself, and how interacting affective and 
cognitive processes, from a perspective of risk, may contribute to the onset of need for care 
and patient status. Finally, to the degree that the affective and cognitive processes in patients 
with psychotic disorder are universal, that is, are quantitative variations of normal human 
mentation,17 more fundamental knowledge is needed on their association in the general 
population, as otherwise a correct interpretation of their role in pathological states such as 
psychotic disorder is not possible.  
 
It has long been recognized that schizophrenia-related pathology is also expressed, at 
attenuated levels, in individuals with „schizotypal“ or „schizoid“ personality traits. Systematic 
review of general population surveys indicates that the experiences associated with 
schizophrenia and related categories, such as paranoid delusional thinking and auditory 
hallucinations, are observed, in an attenuated form, in 5%–8% of healthy people.18 These 
attenuated expressions may be conceived as the behavioral expression of the underlying 
distributed liability for schizophrenia and related disorders, just as higher levels of blood 
pressure express higher liability for cardiovascular disease in a dose-response fashion. This 
interpretation is validated by longitudinal research showing a link between psychotic 
experiences in the general population and later outcomes of psychotic disorder. Since the 
seminal study by Chapman and colleagues,19 there is replicatory evidence from 2 birth 
cohorts20,21 and 3 representative general population cohorts22–24 that low-grade psychotic 
experiences such as delusional thinking and mild hallucinatory experiences may precede the 
diagnosis of psychotic disorder, including clinical diagnosis of schizophrenia requiring 
hospital admission by many years. It has been shown that particularly persistence of 
subclinical psychotic experiences over time is associated with increased risk of later transition 
to clinically relevant psychosis.22,25 Additional evidence is provided by a body of work on 
help-seeking individuals with low-grade psychotic experiences who, when followed over 
time, display high conversion rates to clinical psychotic disorder.26  
 
Therefore, epidemiological research in the general population can be useful in complementing 
clinical research on the link between affective dysregulation, emotional salience 
misattribution, and psychosis, particularly when a longitudinal perspective can be added in 
order to clarify the direction of effects and to study the relationship with onset of impairment. 
Earlier general population surveys in Greece and the Netherlands have shown a high degree 
of overlap between psychotic experiences and affective symptoms below the threshold for 
clinical disorder.27–31 For the current study, it was hypothesized that (1) level of affective 
dysregulation, in the form of depression or (hypo) mania symptoms (regardless of the 
presence of formal mood disorder) in the general population, would be strongly and linearly 
associated with experience of reality distortion, expressed as psychotic experiences, (2) 
presence of affective dysregulation would be associated with persistence of reality distortion 
over time, and (3) affective dysregulation would be associated with Psychotic Impairment in 
the context of reality distortion.  
 
Methods  
 
Study Design and Population  
 
The Early Developmental Stages of Psychopathology (EDSP) study is a prospective-
longitudinal cohort community study which collected data on the prevalence, incidence, risk 
factors, comorbidity, and course of mental disorders. Following ethics committee approval, a 
representative population sample was randomly drawn from the 1994 German government 
population registers. The sample consisted of adolescents and young adults living in the 
Munich area aged 14–24 years at baseline. Because the primary goal of the study was to 
examine the incidence and developmental risk factors for psychopathology, stratification of 
the sample was performed by sampling 14- and 15-year-olds, presumed to have the highest 
incidence density, at twice the rate of 16- to 21-year olds, and by sampling 22- to 24-year-olds 
at half this rate. The 4809 sampled individuals were approached through letter and phone. Of 
these, 4263 were located and determined to be eligible for the study. Most interviews took 
place at the participant’s home. The study consisted of a baseline survey (T0, n = 3021) and 3 
follow-up investigations (T1, T2, and T3), covering a time period of approximately 1.6 years 
(T0–T1, SD = 0.2), 3.5 years (T0–T2, SD = 0.3), and 8.6 years (T0–T3, range 7.4–10.6 years, 
SD = 0.7), respectively. Written informed consent was obtained from all participants. The 
study design and sample have been described in detail in previous reports.27,28   
 
Instruments  
 
Interviews were conducted using the Computer-Assisted Personal Interview (CAPI) version 
of the Munich- Composite International Diagnostic Interview (DIA-X/M-CIDI29), an updated 
version of the World Health Organization’s CIDI version 1.2. The DIA-X/M-CIDI is a 
comprehensive, fully standardized diagnostic interview and assesses symptoms, syndromes, 
and diagnoses of various mental disorders in accordance with the definitions and criteria of 
DSM-IV, along with information about onset, duration, severity, and psychosocial 
impairment. The CIDI is divided into 16 sections: a sociodemographic section, 12 sections 
consisting of 288 symptom questions regarding groups of mental disorders and 3 final 
sections containing concluding questions, interviewer observations, and interviewer ratings. 
High validity 30 as well as high interrater and test-retest reliability of the CIDI have been 
established.31,32 In order to ensure reliability of the assessments, fully trained and experienced 
clinical psychologists who were allowed to probe with clinical follow-up questions conducted 
the interviews. At baseline, the lifetime version of the DIA-X/M-CIDI was used; for the 
follow-up interviews, the DIA-X/M-CIDI interval version was used, covering the respective 
time periods between interviews. As data on the DIA-X/M-CIDI G-section concerning 
psychosis and its clinical relevance were only collected at T2 (lifetime version, assessing 
lifetime cumulative incidence up to T2) and T3 (interval version, assessing onset of new, 
incident, symptoms or interval rate of any symptom between T2 and T3), the current analyses 
are limited to T2 and T3. The response rate was 84% at T2 (n = 2548) and 73% at T3 (n = 
2210), covering an interval period of 4.9 years on average (SD = 0.6).  
 
Assessment of Reality Distortion  
 
Information from the CIDI psychosis section and the clinical interview rating section with its 
embedded Brief Psychiatric Rating Scale33 were used to derive measures of the psychosis 
dimensions. In order to calculate measures of frequency of psychopathological experiences, 
such as lifetime cumulative incidence and interval incidence rates, as well as persistence 
estimates, discrete variables indicating their presence or absence across interview waves were, 
per definition, necessary.  
 
Reality distortion, expressed as psychotic experiences, was the focus of the current analyses. 
All expressions of psychotic experiences, regardless of the presence of a formal psychotic 
disorder, were included. Psychotic experiences were assessed at T2 and T3 using the DIA-X/ 
M-CIDI core psychosis section on delusions (14 items), hallucinations (5 items), and passivity 
(1 item). Specifically, items used were G1, G2a, G3–G5, G7–G13, G13b, G14, G17, G18, 
G20, G20c, G21, and G22a. These items concern classic psychotic symptoms including but 
not limited to persecution, thought interference, and passivity phenomena. Participants were 
first asked to read a list of all the psychotic experiences and then asked whether they ever 
experienced such symptoms by the psychologist (list and phrasing available upon request). 
All these psychosis items can be rated in 2 ways: 1 (absent) and 5 (present), without 
intermediate levels. The presence of positive psychotic experiences was defined as any rating 
of „5“ on any of the 20 DIA-X/M-CIDI core psychosis items.22 In order to examine dose-
response as a function of level of psychotic experiences, an additional variable was 
constructed reflecting the presence of 0, 1, 2, or 3 or more psychotic experiences (hereafter: 
Psychosis Load).  
 
Assessment of Psychotic Impairment  
 
In order to assess functional impact of psychotic experiences, secondary dysfunction and 
help-seeking behavior were examined in individuals with evidence of DIA-X/MCIDI 
psychotic experiences at T2 and T3; the following procedures were followed as described in 
an earlier report. 22 First, 2 DIA-X/M-CIDI psychosis section items for help-seeking were 
used: G16 (delusions) and G23 (hallucinations). These items were phrased as follows: „Did 
you tell a doctor about.(insert the psychosis section beliefs/experiences previously 
acknowledged by the participant along with a visual representation from the response booklet) 
you have had?“ These items were rated in a dichotomous manner (0 = no, 1 = yes). In 
addition, participants were shown a list on which several types of outpatient or inpatient 
institutions for mental health problems were mentioned, ranging from general practitioner or 
school psychologist to psychiatric sheltered housing, and asked whether they had ever sought 
help at any of these institutions because of psychotic symptoms as elicited in the DIA-X/M-
CIDI G-section. This item was rated in a dichotomous manner (0 = no, 1 = yes). Using these 3 
help-seeking items, a dichotomous variable „Help-seeking“ was constructed, indicating 
whether help-seeking behavior had been present (1) or absent (0).  
 
Second, the level of dysfunction related to psychotic experiences was assessed using the DIA-
X/M-CIDI items G28, G29, G29a, and G36. The dysfunction score assessed the effect of the 
psychotic experiences on: (1) feeling upset, unable to work, go places, or enjoy oneself, at the 
time of having these experiences (item G28); (2) being less able to work since these 
experiences began (item G29); (3) being less able to make friends or enjoy social 
relationships since these experiences began (item G29a); and (iv) how much their life and 
everyday activities were impaired when these experiences were at their worst (item G36). 
These 4 psychosis section items were rated in a dichotomous manner (0 = no, 1 = yes). A 
dichotomous variable „Dysfunction“ was constructed, representing a positive answer on any 
of the 4 questions (value label 1) vs negative answers on all 4 questions (value label 0).  
 
Based on these 2 assessments, a combined outcome was created (hereafter „Psychotic 
Impairment“). Psychotic Impairment was absent and scored as „0“ for subjects scoring „0“ on 
both help-seeking behavior and dysfunction. Subjects scoring „1“ on either or both help-
seeking behavior and dysfunction scored „1“ on Psychotic Impairment.  
 
Validation of this variable using third variables was presented previously,22 using 2 variables: 
Caseness and Antipsychotic Treatment. Briefly, The X16 DIA-X/MCIDI item rated the 
interviewer’s opinion regarding clinical evidence of psychological ill-health in 4 levels: 
essentially not noticeable (0), not very noticeable (1), clearly ill (2), and very ill (3). The 
dichotomous variable ‘Caseness’ indicated individuals with a noticeable level of psychiatric 
caseness (any score above „1“). As part of the CIDI treatment module, participants were 
shown a list of different types of medication, rating their use because of any 
psychopathological or psychosomatic problem. The acknowledgement of any antipsychotic 
medication (Q1EA4) reported at T2 and T3 was used to derive treatment („Antipsychotic 
Treatment“: 0 = no, 1 = yes). Validation analyses revealed that Psychotic Impairment was 
strongly associated with both the Caseness (odds ratio [OR] = 10.3, 95% confidence interval 
[95% CI] = 7.0– 15.2) and the Antipsychotic Treatment (OR = 15.3, 95% CI = 6.1–38.4) 
variable.  
 
Assessment of Affective Dysregulation  
 
Affective dysregulation was assessed at T2 and T3 using the 28 symptom items (DSM-IV and 
International Classification of Diseases, Tenth Revision [ICD-10]) of the DIA-X/M-CIDI 
depression and dysthymia section (items regarding feeling depressed, loss of interest, loss of 
energy, hopelessness, decreased concentration, loss of appetite, weight loss, sleep 
disturbances, feelings of worthlessness or guilt, decreased self-esteem, and suicidal 
ideation/attempt) and the 11 symptom items of the DIAX/M-CIDI mania section (items 
regarding increase in goal-directed activity, psychomotor agitation, spending sprees, sexual 
indiscretions, increased talkativeness, flight of ideas, increased self-esteem or grandiosity, 
decreased need for sleep, and distractibility). Symptom items were rated either yes or no. 
Depression symptoms were only rated if present for at least 2 weeks; (hypo)mania symptoms 
if present for at least 4 successive days. In case the participant endorsed the presence of a 
particular symptom, additional probes ascertained whether the symptom was the direct result 
of alcohol or drug use or of physical diseases or conditions. If this were the case, the CIDI 
codes for substance use or somatically induced symptoms were used, and the item was not 
counted toward the diagnosis of a primary mood disorder. Furthermore, symptoms were only 
assessed and rated if at least one of the DIA-X/M-CIDI core depressive (depressed mood or 
loss of interest/pleasure) or core (hypo)mania symptoms (unusual happiness or excitement or 
unusual irritability) was present. Only participants having core (hypo)mania symptoms that 
were either noticed by others or because of which participants experienced problems were 
included.  
 
Binary and Continuous Affective Variables  
 
Both binary and continuous affective variables were constructed as described previously34–36:  
 
i) „Binary (hypo)mania“ and „binary depression“: An a priori binary (hypo)mania variable 
was defined as at least 2 DIA-X/M-CIDI mania symptoms and a binary depression variable as 
at least 3 DIA-X/M-CIDI depression symptoms.  
 
ii) In addition, guided by previous work,34–36 a continuous „(Hypo)mania Score“ and a 
continuous „Depression Score“ variable were constructed. These variables represented 2 
continuous sum scores of symptom ratings: a sum score of (hypo)mania symptoms with a 
minimum of 0, and a maximum score of 11 endorsements (hereafter: „(Hypo)mania Score“), 
and a sum score of depression symptoms with a minimum of 0, and a maximum score of 28 
endorsements (hereafter: „Depression Score“).  
 
iii) Subsequent to (ii), we created, for both symptom groups, progressively stricter and 
overlapping subcategories of these sum scores, indicating the degree of symptom loading. For 
depression, 6 categories were created of no symptoms (0), at least 1 symptom (1), at least 3 
symptoms (2), at least 5 symptoms (3), at least 7 symptoms (4), and at least 9 symptoms (5). 
For (hypo)mania, the categories were similar except that the highest category was at least 5 
symptoms due to the very small number of subjects with 6 or more symptoms.  
 
Statistical Analysis  
 
Analyses were conducted in STATA, version 10.37 Associations were expressed as OR and 
95% CIs derived from logistic regression.  
 
Associations Between Affective Dysregulation and Psychotic Experiences. Cumulative 
incidence measures of affective dysregulation and psychotic experiences up until T2 were 
tested for association in order to establish their lifetime comorbidity (risk set n = 2524). 
Similarly, interval incidence of psychotic experiences at T3 (i.e., individuals with psychotic 
experiences at T3 free from psychotic experiences at T2) were modeled as a function of 
measures of level of affective dysregulation at T3 (risk set n = 1564). This latter analysis 
provided a temporally more precise test of the hypothesis that affective dysregulation 
accompanies the onset of psychotic experiences. Finally, T2 and T3 associations between 
individual psychotic experiences on the one hand and the level of depressive and (hypo)mania 
symptoms on the other were tested in order to gain insight in possible patterns of association 
between specific psychotic experiences and affective dysregulation.  
 
Psychosis Persistence. In order to assess the association between level of affective 
dysregulation and persistence of psychotic experiences over the period T2–T3, associations 
between T3 level of affective dysregulation and T3 psychotic experiences were assessed in 
individuals with evidence for psychotic experiences at T2 (risk set n = 464).  
 
Psychotic Impairment. In order to assess the relationship between level of affective 
dysregulation and incident Psychotic Impairment, associations between T3 Psychotic 
Impairment and T3 level of affective dysregulation were assessed in individuals with 
evidence of psychotic experiences at T3 but free from Psychotic Impairment at T2 (risk set n 
= 191).  
 
Results  
 
At T2, over half (51%) of the sample was male and the mean age was 21.7 years (SD 3.4). At 
T2, 574 (23%) of all subjects presented with one or more lifetime psychotic experiences, with 
a stronger representation of delusions (21%) compared with hallucinations (5%). At T3, the 
rates were lower, representing only the occurrence of psychotic experiences over the interval 
from T2 to T3 (table 1). At T2, 978 subjects (32%) had experienced 2 or more (hypo)mania or 
3 or more depression symptom; at T3, this was the case for 925 subjects (31%). Within the 
subgroup of subjects with 2 or more (hypo)mania or 3 or more depression symptoms at T2 (n 
= 978), 57% did not report similarly defined (hypo)mania or depression symptoms at T3. 
Conversely, within the subgroup of subjects that did not experience 2 more (hypo)mania or 3 
or more depression symptoms at T2, 25% did present similarly defined (hypo)mania or 
depression symptoms at T3. The lifetime cumulative incidence up until T2 and the T2–T3 
interval rates, assessed at T3, of hallucinations, delusions, (hypo)mania, and depression 
symptoms are provided in table 1.  
 
Affective Dysregulation and Reality Distortion Co-occurrence  
 
Of the 574 subjects with psychotic experiences, 35% also presented with at least 2 
(hypo)mania symptoms at T2, compared with 15% of subjects without lifetime psychotic 
experiences at T2. At T3, these figures were 27% and 11%, respectively. Similarly, 43% of 
the 574 subjects with psychotic experiences presented with at least 3 depression symptoms at 
T2, compared with 23% of subjects without psychotic experiences. At T3, these figures were 
46% and 31%, respectively. At both T2 and T3, the majority of psychotic experiences 
occurred in the context of affective dysregulation (at least 2 (hypo)mania symptoms or at least 
3 depression symptoms; table 2).  
 
Bidirectional Dose-Response Associations Between Affective Symptoms and Reality 
Distortion  
 
The probability of lifetime psychotic experiences at T2 was progressively higher with greater 
level of co-occurrent affective dysregulation in a dose-response fashion ((Hypo) mania Score 
OR linear trend over 4 levels = 1.70, 95% CI: 1.55, 1.87; P < .001; Depression Score OR 
linear trend over 6 levels: OR = 1.31, 95% CI: 1.24, 1.38; P < .001; table 3). Incident 
psychotic experiences at T3 (ie psychotic experiences at T3 in subjects free from psychotic 
experiences at T2) were similarly associated with (Hypo)mania Score and Depression Score 
in a dose-response fashion (table 3).  
 
Similarly, the above OR linear trends expressing the association between psychotic 
experiences and affective dysregulation became progressively greater at higher level of 
Psychosis Load, both for mania and depression, and both at T2 and at T3 (table 4).  
 
Psychosis Persistence  
 
(Hypo)mania Score and Depression Score were associated with persistence of psychotic 
experiences over the period T2–T3. Thus, within the sample of subjects with psychotic 
experiences at T2 and interviewed again at T3 (risk set n = 464), the probability of persistence 
of psychotic experiences was progressively greater with higher (Hypo)mania Score (OR linear 
trend 4 categories = 1.51; 95% CI: 1.22, 1.88; P < .001) and higher Depression Score (OR 
linear trend 6 categories = 1.15; 95% CI = 1.03, 1.28; P = .012).  
 
Psychotic Impairment  
 
In all, 228 subjects (9%) presented at T2 with Psychotic Impairment. At T3, the number with 
Psychotic Impairment was 118 (5%). Of these 118, 70 subjects had not presented previously 
with Psychotic Impairment at T2, representing incident Psychotic Impairment. Affective 
dysregulation was associated with incident Psychotic Impairment: within the sample of 
subjects without Psychotic Impairment at T2 and presence of at least one psychotic 
experience at T3 (risk set n = 191), the probability of Psychotic Impairment at T3 as 
progressively higher with higher (Hypo)mania Score at T3 (OR linear trend 4 categories = 
1.37, 95% CI: 1.02, 1.83; P = .036) and higher Depression Score at T3 (OR linear trend 6 
categories = 1.28, 95% CI: 1.10, 1.49; P = .002).  
 
Associations Between Affective Dysregulation and Specific Psychotic Experiences  
 
An overview of specific psychotic experiences and associations with binary depression (at 
least 3 symptoms) and (hypo)mania (at least 2 symptoms) variables is provided in table 5. For 
both depression and (hypo)mania symptoms, no specific trend or pattern was apparent among 
the different psychotic experiences.  
 
Discussion  
 
Clinical studies in help-seeking samples suggest that early intervention in the prodromal 
phase of psychotic disorder may be feasible.38 However, knowledge on the developmental 
mechanisms underlying the epidemiology of prodromal states in the general population 
remains very limited. The current study connects reality distortion and affective dysregulation 
in a general population setting from a perspective of risk and a perspective of understanding 
links with normal mentation. The results suggest that psychotic experiences in the general 
population are nonspecifically associated with affective dysregulation, in a bidirectional dose-
response fashion. Second, persistence of psychotic experiences and the onset of impairment 
associated with reality distortion occur more often if there is a context of affective 
dysregulation.  
 
Coexpression as a Reflection of Overlapping Genetic Liabilities  
 
Although the delusions and hallucinations of psychosis can be readily recognized, classifying 
psychotic states remains a major challenge. Psychosis is not exclusive to schizophrenia and 
occurs across a range of diagnostic categories of psychotic disorder and even among the 
category of nonpsychotic mood disorders.39 The criteria used to distinguish between the 
different categories of psychotic disorder are based on duration, dysfunction, associated 
substance use, „bizarreness“ of delusions, and presence of depression or (hypo)mania. 
However, the resulting diagnostic categories of psychotic disorder show overlap in genetic 
liability among themselves. For example Kendler and colleagues40 demonstrated a significant 
familial relationship between nonschizophrenic psychotic disorders with both schizophrenia 
and schizotypal personality disorder. Family and twin studies similarly demonstrate a degree 
of overlap in genetic liability between nonaffective psychotic disorder and bipolar disorder.3–5  
 
Coexpression of (subclinical) affective dysregulation and psychotic experiences in general 
cohort studies may, thus, in part reflect overlapping distributed genetic vulnerabilities. The 
majority of general cohort studies on transition rates from subclinical symptoms to clinical 
syndromes did not examine coexpression of reality distortion and affective dysregulation. 
Multiple studies suggest that subclinical psychotic experiences increase the risk for 
nonaffective psychotic disorder,19–24 and similarly subthreshold depression and/or 
(hypo)mania symptoms have been shown to increase the risk for bipolar disorder.35,36 Overall, 
affective dysregulation and reality distortion have been shown to represent the behavioral 
expression of risk for more severe psychotic states including schizophrenia and bipolar 
disorder in the general population. In light of the accumulating evidence on overlap in genetic 
liability,3–5 suggesting a broad underlying vulnerability that expresses across the different 
categories, our findings of associations between affective dysregulation and psychotic 
experiences in the general population may therefore simply reflect passive clustering of the 
behavioral expression of overlapping genetic risks.  
 
Coexpression as a Reflection of Causal Influence  
 
The fact that coexpression of affective dysregulation predicted persistence of reality distortion 
and impairment associated with psychotic experiences suggest that, in addition to correlated 
genetic liabilities, a direct impact of affective dysregulation on the onset of psychotic 
experiences may be hypothesized. Existent psychological models of symptom formation 
suggest that the emotional context, and associated beliefs or appraisals, may induce bias in 
logical reasoning processes and, therefore, provoke reality distortion in healthy individuals.2,15 
In the psychological model described by Garety and colleagues,1 the experience of a stressful 
event is thought to potentially give rise to altered preexisting beliefs and ongoing appraisals of 
experiences due to a certain emotional change or a cognitive processing bias. These distorted 
processes may lead to aberrant experiences that may seem personally significant to the 
individual and are likely to trigger a search for an explanation as to their meaning and cause 
that is consistent with affect-associated beliefs. Biased appraisal processes may contribute to a 
judgment that the experience is in fact externally caused. It is the interpretation that causes the 
associated distress and disability, rather than the experience itself. Thus, maladaptive 
appraisal patterns, induced by emotional processes, are suggested to increase the risk for 
positive symptom formation in vulnerable individuals.1 Our findings provide support for a 
cognitive model of symptom formation, by demonstrating involvement of affective processes 
in the onset and persistence of reality distortion outside the context of disorder.  
 
Linking Genetic and Cognitive Mechanisms  
 
Evidence on the role of cognitive processes suggests that cognitive biases and appraisals can 
help explain onset of psychosis.1 Attempts have been made to integrate cognitive and 
neurobiological theories into a single model of psychotic states.1,16,41 Thus, evidence indicates 
that genetic risk for psychotic disorder is associated with underlying alterations in the 
dopamine system, including increased dopamine synaptic availability,42 increased striatal 
dopamine synthesis,43,44 and increased dopamine reactivity to stress.45,46 Under normal 
circumstances, it is the context-driven activity of the dopamine system that mediates the 
experience of novelty and the acquisition of appropriate motivational salience, detecting new 
rewards in the environment that facilitate learning and goal-directed behavior. Certain 
cerebral vulnerabilities, occasioned by interplay between genetic and environmental risks, 
could trigger context-independent or context-inappropriate release of dopamine. A 
dysregulated dopamine system may cause aberrant assignment of salience and motivational 
significance to external objects (leading to delusions) and internal representations of percepts 
and memories (leading to hallucinations).47 Thus, theory derived from existent psychological 
models of psychotic symptom formation predicts that affective dysregulation may impact 
directly on risk for reality distortion. An integrated model would additionally suggest that the 
risk to develop a clinical disorder is particularly high in those who additionally have a genetic 
liability for dopaminergic dysregulation, facilitating aberrant salience attribution.  
 
Limitations  
 
Several limitations should be taken into account when interpreting these results. First, the 
study was epidemiological, and no direct measurements of affective and cognitive processes 
such as aberrant salience attribution were available, limiting the explanatory power of the 
findings on these mechanisms. Second, although longitudinal, measurements were too far 
apart for dynamic models of the onset of impairment as a function of affective dysregulation. 
Third, assessment of psychotic experiences, while better than lay-interviewer assessed self-
reports, will likely contain false-positive answers even when interviewers are clinical 
psychologists. However, it is unlikely that false-positive assessments would produce spurious 
associations with affective dysregulation – the opposite, more conservative alternative is more 
likely. Furthermore, the substantial literature on self-reported psychotic experiences, 
including those assessed with the DIA-X/MCIDI, indicates substantial predictive and other 
forms of validity of these phenomena.18 Fourth, lifetime rates in excess of 22% may seem 
high, given an estimate of 5%–8% in a recent systematic review.18 However, in another 
systematic review we are preparing, it is apparent that rates of psychotic experiences are 
critically dependent on the number of items assessing different psychotic experiences. 
Previous work using the CIDI also detected rates close to 20%.48 Finally, it could be argued 
that the measure of psychotic Impairment used was broad, resulting in a lifetime rate of 9%, 
which may be considered very high for psychosis. The high rate is in part inherent to the 
population-based research paradigm of EDSP, which will always detect many more cases 
compared with the much lower administrative rates reflecting treatment at the level of 
services. Furthermore, even the rate of narrowly defined clinical psychotic disorder, when 
assessed completely, may be as high as 3.5%.49 In addition, to the degree that our definition of 
impairment was broad, it can be argued that in this context, sensitivity is more important than 
specificity, given the fact that the main clinical application of research on extended 
phenotypes ultimately is situated in the area of early detection.  
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